How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings results on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.19).

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include SCYNEXIS (SCYX) , Xtrackers California Municipal Bond ETF (CA) , Endologix (ELGX) , Energy Transfer (ET) , TG Therapeutics (TGTX) , BlackRock (BLK) , Fate Therapeutics (FATE) , Pfizer (PFE) , Spectrum Pharmaceuticals (SPPI) and Esperion Therapeutics (ESPR) .

NASDAQ:ZFGN

Zafgen (ZFGN) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ZFGN Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $6.33
▼
$7.00
50-Day Range: $0.99
▼
$25.06
52-Week Range: $0.62
▼
$2.76

Volume: 510,792 shs
Average Volume: 360,199 shs
Market Capitalization: $239.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Social Media

Get Zafgen alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Zafgen Stock (NASDAQ:ZFGN)

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

ZFGN Stock News Headlines

April 9, 2023 | marketwatch.com

Global Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030

February 26, 2023 | thestreet.com

Zafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug Results

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

January 13, 2023 | thestreet.com

Zafgen (ZFGN) Stock Surges on Positive Obesity Drug Trial

November 8, 2022 | bbc.co.uk

Food and drink in a castle

September 30, 2022 | seekingalpha.com

LRMR Larimar Therapeutics, Inc.

September 14, 2022 | streetinsider.com

Form 424B5 Larimar Therapeutics, - StreetInsider.com

April 12, 2022 | streetinsider.com

Form DEF 14A Larimar Therapeutics, For: May 10 - StreetInsider.com

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 25, 2022 | marketscreener.com

LARIMAR THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

November 12, 2021 | marketscreener.com

LARIMAR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com

November 12, 2021 | streetinsider.com

Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results - StreetInsider.com

November 12, 2021 | globenewswire.com

Larimar Therapeutics Reports Third Quarter 2021 Operating - GlobeNewswire

October 22, 2021 | finance.yahoo.com

Anti-Obesity Therapeutics Market Research Report by Mechanism of Action, by Drug Type, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo Finance

October 20, 2021 | benzinga.com

Anti-Obesity Therapeutics Market Research Report by Mechanism of Action, by Drug Type, by Region - Global - Benzinga

September 21, 2021 | streetinsider.com

Fauna Bio Raises $9 Million to Expand Comparative Genomics Platform for Novel Target Discovery - StreetInsider.com

September 21, 2021 | prnewswire.com

Fauna Bio Raises $9 Million to Expand Comparative Genomics Platform for Novel Target Discovery - PRNewswire

August 2, 2021 | seekingalpha.com

Vividion Therapeutics Begins U.S. IPO Effort - Seeking Alpha

See More Headlines

Receive ZFGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zafgen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2020
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ZFGN
CUSIP: N/A
CIK: 1374690
Web: www.zafgen.com
Phone: 617-622-4003
Fax: N/A
Employees: 38
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-45,410,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -51.34%
Return on Assets: -34.55%

Debt

Debt-to-Equity Ratio: 0.26
Current Ratio: 6.56
Quick Ratio: 6.56

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.35 per share
Price / Book: 4.73

Miscellaneous

Outstanding Shares: 37,470,000
Free Float: N/A
Market Cap: $239.06 million
Optionable: Not Optionable
Beta: 0.27

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. Jeffrey S. Hatfield (Age 61)
CEO & Director
Ms. Patricia L. Allen (Age 57)
Chief Financial Officer
Dr. Dennis D. Kim M.D. (Age 49)
MBA, Chief Medical Officer
Dr. James E. Vath (Age 58)
Head of Discovery & Devel.
Mr. Brian P. McVeigh (Age 46)
Chief Bus. Officer

Key Competitors

View All Competitors

ZFGN Stock Analysis - Frequently Asked Questions

How were Zafgen's earnings last quarter?: Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings results on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.19).
What other stocks do shareholders of Zafgen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include SCYNEXIS (SCYX), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Energy Transfer (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Pfizer (PFE), Spectrum Pharmaceuticals (SPPI) and Esperion Therapeutics (ESPR).

This page (NASDAQ:ZFGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zafgen (ZFGN) Stock Price, News & Analysis

About Zafgen Stock (NASDAQ:ZFGN)

ZFGN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ZFGN Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info